CAV regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[doxorubicin]] and [[vincristine]] used for the treatment of extensive-stage small cell lung cancer.<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | {{PAGENAME}} refers to a regimen consisting of [[cyclophosphamide]], [[doxorubicin]] and [[vincristine]] used for the treatment of [[small cell lung cancer|extensive-stage small cell lung cancer]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|A|Doxorubicin (Adriamycin)}} | |||
{{chemo|V|Vincristine}} | |||
==Indications== | ==Indications== | ||
* [[Small cell lung cancer|Extensive-stage small cell lung cancer]]<ref name="pmid2831819">{{cite journal| author=Kawahara M, Tsuruta M, Furuse K, Arai R, Kodama N, Yamamoto M et al.| title=[Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer]. | journal=Gan To Kagaku Ryoho | year= 1988 | volume= 15 | issue= 3 | pages= 457-62 | pmid=2831819 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2831819 }} </ref> | * [[Small cell lung cancer|Extensive-stage small cell lung cancer]]<ref name="pmid2831819">{{cite journal| author=Kawahara M, Tsuruta M, Furuse K, Arai R, Kodama N, Yamamoto M et al.| title=[Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer]. | journal=Gan To Kagaku Ryoho | year= 1988 | volume= 15 | issue= 3 | pages= 457-62 | pmid=2831819 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2831819 }} </ref> |
Latest revision as of 14:31, 11 March 2015
WikiDoc Resources for CAV regimen |
Articles |
---|
Most recent articles on CAV regimen Most cited articles on CAV regimen |
Media |
Powerpoint slides on CAV regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on CAV regimen at Clinical Trials.gov Clinical Trials on CAV regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on CAV regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on CAV regimen Discussion groups on CAV regimen Patient Handouts on CAV regimen Directions to Hospitals Treating CAV regimen Risk calculators and risk factors for CAV regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for CAV regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:CAV Regimen; Cytoxan-Adriamycin-Vincristine Regimen; VAC Regimen
Overview
CAV regimen refers to a regimen consisting of cyclophosphamide, doxorubicin and vincristine used for the treatment of extensive-stage small cell lung cancer.[1][2]
Regimen
CCyclophosphamide
ADoxorubicin (Adriamycin)
VVincristine
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Kawahara M, Tsuruta M, Furuse K, Arai R, Kodama N, Yamamoto M; et al. (1988). "[Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer]". Gan To Kagaku Ryoho. 15 (3): 457–62. PMID 2831819.